Long-term acid suppression increases bacterial overgrowth, Clostridioides difficile and other enteric infections, and changes the gut microbiome.
Original statement
حمض المعدة ليس عدوّاً يجب قمعه، بل أداة أساسية للهضم وقتل الميكروبات وامتصاص الحديد وفيتامين ب12 والكالسيوم والمغنيزيوم. تثبيطه لفترات طويلة بـ PPIs (أوميبرازول، نكسيم، كونترلوك) أو مثبطات H2 ينقلب على الجسم: مرض كلوي مزمن، فرط نمو بكتيري، عدوى مطثية عسيرة، التهاب رئوي، نقص B12 والمغنيزيوم، كسور ورك، تغيّر الميكروبيوم، وزيادة الوفيات. والأخطر أنّ الجسم يدمن الدواء عبر فرط الإفراز الارتدادي بعد الإيقاف، فيتحوّل الاستخدام القصير إلى اعتماد مزمن.
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Long-term acid suppression increases bacterial overgrowth, Clostridioides difficile and other enteric infections, and changes the gut microbiome.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (eltayebat.com); not verified as Elawady's own words
- Origin
- https://eltayebat.com/rule/acid-blockers/
- Attribution uncertainty
- Written by the archive operators; study selection is the archive's, not necessarily Elawady's.
- Claimed mechanism
Removal of the gastric acid barrier allows oral and upper-GI bacteria to reach and colonise the lower gut.
- Claimed health effect
C. difficile infection, enteric infections, SIBO, reduced microbiome diversity.
- Population concerned
PPI users.
- Geographic restriction by Elawady
none found
Diverging source versions
أدوية مثبطات الحموضة ممنوعة عندي بشكل دائم — هي سموم تسبب الكبد الدهني والقولون العصبي، وتمنع الجسم من الاستفادة من الطعام وامتصاص الحديد وفيتامين ب12 والمعادن، وتعالج الأعراض فقط بينما تفاقم المشاكل الأساسية من نمو بكتيري وسوء هضم.
- Source status
- Archive quote (no location given)
- Attribution
- Elawady (archive paraphrase; source video not given)
- Origin
- https://eltayebat.com/rule/acid-blockers/
Scientific assessment
Mostly true – Correct at its core, but with limitations or minor inaccuracies.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Acid blockers favour bacterial overgrowth and gut infections and alter the microbiome.
2. What is demonstrably correct?
This is largely correct. The COMPASS RCT found more enteric infections with pantoprazole (1.4% vs 1.0%; OR 1.33, 95% CI 1.01–1.75); meta-analyses report pooled ORs of about 1.7–2.0 for C. difficile; twin and population cohorts show lower diversity and more oral bacteria in the stool of PPI users.
3. What is wrong or exaggerated?
The size of the C. difficile effect is uncertain (high heterogeneity, publication bias). SIBO was associated with PPI use only when diagnosed by aspirate culture, not by breath test. 'Microbiome change' is not the same as proven disease.
4. What remains unclear?
Long-term clinical consequences of the microbiome shifts beyond infection are not established.
5. Which studies support it?
A-PPI-05, A-PPI-06, A-PPI-15, A-PPI-16, A-PPI-17; COMPASS (I-PPI-01) for enteric infections.
6. Which studies contradict it?
COMPASS: C. difficile was about twice as common with pantoprazole but with only 13 events and no statistical significance.
7. What applies to Germany and Europe?
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
8. What is known about Egypt?
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
9. What practical conclusion is appropriate?
This is a valid reason to avoid PPIs without a clear indication, especially in hospitalised or antibiotic-treated people, but not a reason to refuse an indicated PPI.
Assessment details
- Rationale for certainty of evidence
Many observational studies and meta-analyses show about 1.7–2-fold odds of C. difficile; microbiome studies consistently show compositional changes; the COMPASS RCT confirmed more enteric infections (OR 1.33) with pantoprazole. Heterogeneity and publication bias in the meta-analyses lower certainty for the exact size.
- Source quality
Supported by meta-analyses, large microbiome cohorts and one large RCT.
- Regional transferability
High; findings come from North America, Europe and Asia.
- Individual exceptions
Absolute risk is low for most users; risk is higher in hospitalised, older and antibiotic-treated people.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Stomach acid kills many bacteria that we swallow. When acid is strongly reduced for a long time, more of these bacteria reach the intestine. Studies show a somewhat higher risk of gut infections, including C. difficile, in people who take PPIs, and a randomised trial confirmed a small increase in gut infections. For most people the absolute risk stays low.
Studies on this claim
Studies supporting the claim (6)
-
PPIs and C. difficile – meta-analysis
Trifan A et al.. World J Gastroenterol 2017 · PMID 29085200 · DOI 10.3748/wjg.v23.i35.6500Meta-analysiscited by the Tayebat archiveabstract only checkedPPI users had about twice the odds of C. difficile infection.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
CDI risk with PPIs.
- How was the study done?
Meta-analysis.
- How many people, animals or samples were studied?
56 studies.
- What was actually found?
Higher odds.
- How large was the observed effect?
OR 1.99.
- What do the results mean in everyday life?
Gut infection risk is a real concern.
- What are the study's limitations?
Heterogeneity, publication bias.
- What does it say about Elawady's specific claim?
Supports.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Exact size; causality.
-
PPIs and C. difficile in hospital
Janarthanan S et al.. Am J Gastroenterol 2012 · PMID 22710578 · DOI 10.1038/ajg.2012.179Meta-analysiscited by the Tayebat archiveabstract only checkedPooled risk about 1.7-fold higher with PPIs.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
CDAD with PPIs.
- How was the study done?
Meta-analysis.
- How many people, animals or samples were studied?
23 studies.
- What was actually found?
Higher incidence.
- How large was the observed effect?
RR ≈1.69.
- What do the results mean in everyday life?
Infection risk.
- What are the study's limitations?
Observational; overlap.
- What does it say about Elawady's specific claim?
Supports.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Causation.
-
PPIs change gut bacteria (TwinsUK)
Jackson MA et al.. Gut 2016 · PMID 26719299 · DOI 10.1136/gutjnl-2015-310861Cross-sectional studycited by the Tayebat archiveabstract only checkedPPI users had fewer typical gut bacteria and more mouth bacteria in stool.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Microbiome with PPIs.
- How was the study done?
Twin cohort + replication.
- How many people, animals or samples were studied?
1,827.
- What was actually found?
Lower diversity, oral bacteria.
- How large was the observed effect?
not a single effect size
- What do the results mean in everyday life?
Explains infection risk.
- What are the study's limitations?
Composition only.
- What does it say about Elawady's specific claim?
Supports.
- Do the results apply to Germany and Europe?
UK.
- What can explicitly not be concluded from this study?
Disease causation.
-
PPIs and the gut microbiome (Netherlands)
Imhann F et al.. Gut 2016 · PMID 26657899 · DOI 10.1136/gutjnl-2015-310376Cross-sectional studycited by the Tayebat archiveabstract only checkedPPI users had less diverse gut bacteria and more potentially harmful bacteria.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Microbiome.
- How was the study done?
3 cohorts.
- How many people, animals or samples were studied?
1,815.
- What was actually found?
Shifts in 20% of taxa.
- What do the results mean in everyday life?
Possible infection link.
- What are the study's limitations?
Cross-sectional.
- What does it say about Elawady's specific claim?
Supports.
- Do the results apply to Germany and Europe?
Dutch.
- What can explicitly not be concluded from this study?
Disease.
-
PPIs and bacterial overgrowth
Lo WK et al.. Clin Gastroenterol Hepatol 2013 · PMID 23270866 · DOI 10.1016/j.cgh.2012.12.011Meta-analysiscited by the Tayebat archiveabstract only checkedAssociation found only with the culture test, not with breath tests.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
SIBO risk.
- How was the study done?
Meta-analysis.
- How many people, animals or samples were studied?
3,134.
- What was actually found?
OR 2.28 overall.
- How large was the observed effect?
OR 2.28.
- What do the results mean in everyday life?
Possible overgrowth.
- What are the study's limitations?
Imprecise.
- What does it say about Elawady's specific claim?
Partly supports.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Clinical relevance.
-
Pantoprazole safety in a large randomised trial
Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056Randomised controlled trialindependent cross-checkfull text checked★ key studyOver three years, only gut infections were more common with pantoprazole (1.4% vs 1.0%).
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test PPI harms in an RCT.
- How was the study done?
Placebo-controlled trial.
- How many people, animals or samples were studied?
17,598 heart/vascular patients.
- What was actually found?
No excess harm except enteric infections.
- How large was the observed effect?
OR 1.33 enteric infections.
- What do the results mean in everyday life?
PPIs are largely safe for 3 years.
- What are the study's limitations?
3-year duration; specific population.
- What does it say about Elawady's specific claim?
Contradicts most broad harm claims; supports infection risk.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Very long-term effects.
No study in this group is marked as key.
Studies contradicting or limiting the claim (0)
No studies in this group.
Studies with mixed or unclear results (1)
-
AGA advice on long-term PPIs
Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031Guideline / position statementindependent cross-checkabstract only checkedPPIs are justified for defined indications; risks do not require routine monitoring.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Risk–benefit guidance.
- How was the study done?
Expert review.
- What was actually found?
10 best practice statements.
- What do the results mean in everyday life?
Use for real indications at lowest dose.
- What are the study's limitations?
Expert opinion.
- What does it say about Elawady's specific claim?
Mixed: supports indication-based use.
- Do the results apply to Germany and Europe?
Applicable.
No study in this group is marked as key.
Regional context
Germany / EU
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
Egypt
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
What applies in my country?
General scientific assessment
Mostly true Correct in substance: PPIs modestly raise the risk of gut infections and alter gut bacteria.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.. Trifan A et al.. World J Gastroenterol 2017 · PMID 29085200 · DOI 10.3748/wjg.v23.i35.6500
- Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.. Janarthanan S et al.. Am J Gastroenterol 2012 · PMID 22710578 · DOI 10.1038/ajg.2012.179
- Proton pump inhibitors alter the composition of the gut microbiota.. Jackson MA et al.. Gut 2016 · PMID 26719299 · DOI 10.1136/gutjnl-2015-310861
- Proton pump inhibitors affect the gut microbiome.. Imhann F et al.. Gut 2016 · PMID 26657899 · DOI 10.1136/gutjnl-2015-310376
- Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.. Lo WK et al.. Clin Gastroenterol Hepatol 2013 · PMID 23270866 · DOI 10.1016/j.cgh.2012.12.011
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
- The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.. Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031